Welcome to our dedicated page for Sonoma Pharmaceu news (Ticker: SNOA), a resource for investors and traders seeking the latest updates and insights on Sonoma Pharmaceu stock.
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) is frequently in the news for developments related to its stabilized hypochlorous acid (HOCl) products based on patented Microcyn technology. The company issues regular updates on product launches, regulatory milestones, distribution partnerships, and financial results, giving investors and industry observers insight into how its HOCl portfolio is being deployed in wound care, eye care, oral and nasal care, dermatological conditions, podiatry, animal health care, and non-toxic disinfectants.
News coverage often highlights Sonoma’s expansion into consumer and professional markets. Recent press releases describe HOCl-based diaper rash products for infants and children launched into large U.S. retailers, hypochlorous acid-based acne products placed in retail pharmacy chains in the United Kingdom, and a Microcyn-based facial spray listed under the FDA’s Modernization of Cosmetics Regulation Act of 2022 (MoCRA). The company also reports on collaborations such as its HOCl wound cleanser manufactured for Medline Industries, LP for distribution into U.S. hospital systems and home healthcare channels.
Regulatory and recognition updates are another key theme. Sonoma has announced successful transition of its European products to the EU Medical Device Regulation (MDR), registrations with the MHRA in the United Kingdom, and multiple seals for Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel from organizations such as the National Psoriasis Foundation and the National Rosacea Society. Financial news includes quarterly and annual results, revenue trends by region, and non-GAAP metrics such as EBITDA loss.
By following the SNOA news feed, readers can monitor how Sonoma’s HOCl-based products are progressing through new markets, how its regulatory footprint is evolving, and how these developments are reflected in reported financial performance and corporate actions.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation in MEDICA 2024, the world's largest medical trade fair, taking place in Düsseldorf, Germany from November 11-14, 2024. The event is expected to attract over 120,000 visitors from 70+ countries and 5,300+ exhibitors. Sonoma will showcase its Microcyn technology-based products for wound care, eye care, dermatological conditions, and other applications at booth F12-5 in Hall 15. The company aims to expand its distributor network and forge new partnerships through this global platform.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has expanded its partnership with a leading global healthcare distributor for marketing and distributing its wound care products in Canada. This amendment to their existing agreement, which previously covered distribution in the United States, now includes over-the-counter wound care products for sale in both countries.
The expanded partnership aims to bring Sonoma's Microcyn® technology based stabilized hypochlorous acid (HOCl) products to Canadian patients, offering improved management of acute and chronic wounds. CEO Amy Trombly highlighted the distributor's expertise and network as key factors in reaching new patients and providing greater accessibility to consumers through over-the-counter products.
Sonoma Pharmaceuticals (Nasdaq:SNOA), a global healthcare leader developing Microcyn® technology based stabilized hypochlorous acid (HOCl) products, has announced its participation in two upcoming investor conferences:
1. Danisavage Financial Strategies Virtual 1x1 Investor Conference on October 24 at 2:00pm ET. CEO Amy Trombly and CFO Jerry Dvonch will be available for one-on-one meetings.
2. LD Micro Main Event XVII on October 29 at 1:30am PT at the Luxe Sunset Blvd Hotel in Los Angeles, CA. The presentation will be webcast live, and one-on-one meetings will be available on October 29-30, 2024.
These conferences provide opportunities for investors to learn more about Sonoma's wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has successfully regained compliance with Nasdaq's minimum bid price rule, avoiding potential delisting. The company, known for its patented Microcyn technology based on stabilized hypochlorous acid (HOCl), implemented a 1-for-20 reverse stock split on August 30, 2024. This action was taken in response to a non-compliance notice received on September 22, 2023, when SNOA's stock price fell below the required $1.00 per share minimum.
Following the reverse split, Sonoma's stock price maintained the required minimum for 10 consecutive business days, satisfying Nasdaq's compliance criteria. The company received formal confirmation from Nasdaq that it has regained compliance, and the matter is now closed. This development ensures Sonoma's continued listing on the Nasdaq Capital Market, maintaining its visibility and access to capital markets.
Sonoma Pharmaceuticals (NASDAQ:SNOA) has received a new FDA 510(k) clearance for its Microcyn technology-based solution, expanding its over-the-counter (OTC) indications. The clearance allows for OTC management of minor skin abrasions, lacerations, and irritations on the face, eyelid, and eyelashes. This development strengthens Sonoma's position in the hypochlorous acid (HOCl) industry, particularly in eye care claims.
The company can now market its OTC dermatology products more broadly, targeting facial applications. Sonoma has also demonstrated safety, efficacy, and stability for a 2-ounce product size, opening up new packaging opportunities for consumer-friendly formats. CEO Amy Trombly emphasized that this clearance validates Sonoma's proprietary technology and expertise in HOCl, developed over two decades.
Sonoma Pharmaceuticals (NASDAQ:SNOA) and EMC Pharma have announced a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line. The collaboration includes:
1. EMC Pharma gaining rights to sell OTC Ocucyn
2. Sonoma gaining rights to sell prescription Acuicyn
3. Introduction of new design and packaging for Ocucyn
4. Presentation of the expanded product line at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024
Both products are based on Sonoma's patented Microcyn technology using stabilized hypochlorous acid (HOCl). This partnership aims to increase sales of both OTC and prescription eye care products by coordinating marketing efforts and expanding market reach.
Sonoma Pharmaceuticals (NASDAQ:SNOA) announced a 1-for-20 reverse split of its outstanding common stock, effective August 29, 2024, at 5:00 pm EDT. Trading on the adjusted basis will begin on August 30, 2024. This move aims to maintain the company's Nasdaq Capital Market listing by meeting the $1.00 minimum bid price requirement before September 16, 2024.
Key points:
- Common stock will reduce from ~20 million to ~1 million shares
- Authorized shares will increase from 24 million to 50 million
- No fractional shares will be issued; cash will be given in lieu
- Proportional adjustments to stock options and equity-compensation plans
- New CUSIP number will be issued
CEO Amy Trombly emphasized the importance of maintaining Nasdaq listing for business confidence and opportunities.
Sonoma Pharmaceuticals (Nasdaq: SNOA) and MicroSafe Group announce that the Australian Therapeutic Goods Administration (TGA) has approved extended claims for Nanocyn® Disinfectant and Sanitizer. The product, manufactured by Sonoma using its patented Microcyn® technology, is now approved for use against Candida auris (C. auris) and Clostridium difficile (C. diff) with a 10-minute kill time.
Previously, Nanocyn® was approved with a 15-second kill time against SARS-CoV-2 and a 30-second kill time against Norovirus, Influenza A (H1N1), and bacteria like MRSA. The U.S. EPA has also approved Nanocyn® as an effective disinfectant against various pathogens. This extended approval highlights Nanocyn®'s broad-spectrum efficacy and its potential to enhance patient safety in healthcare settings.
Sonoma Pharmaceuticals (Nasdaq: SNOA) has announced a distribution agreement with a leading global healthcare distributor for its wound care products in the United States. The partnership will leverage the distributor's extensive network of hospital systems and healthcare channels to expand Sonoma's wound care business across the country.
Sonoma's products are based on their patented Microcyn® technology, which uses stabilized hypochlorous acid (HOCl) for various applications including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care. CEO Amy Trombly described the partnership as a "huge step forward" for the company's U.S. wound care business expansion.
Additional details about the agreement can be found in Sonoma's Current Report on Form 8-K filed with the SEC on August 21, 2024.
Sonoma Pharmaceuticals (NASDAQ: SNOA) reported financial results for Q1 FY2025 ended June 30, 2024. Key highlights include:
- European revenues increased 20% year-over-year
- Gross margin improved to 39% from 35% in the same period last year
- Net loss decreased by 19% compared to Q1 FY2024
- Total revenues remained flat at $3.4 million
- Operating expenses were nearly flat year-over-year at $2.5 million
- EBITDA loss remained stable at $1.0 million
- Cash and cash equivalents stood at $2.6 million as of June 30, 2024
The company expanded its product offerings and partnerships, including a new distribution agreement in Ukraine and increased presence in U.S. retail stores for its animal health care products.